Objective
Assess safety & effectiveness in achieving patency of target venous lesion through 12 months post stent placement, in patients with obstruction of the iliofemoral venous outflow tract.
Trial Design
Prospective, multi-center (22 sites in the US and Europe) single arm, non-randomized.
Key Inclusion Criteria
Unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof
- ≥50% reduction in target vessel lumen diameter (venogram) Clinically significant venous obstruction defined as: CEAP “C” ≥3 OR VCSS Pain ≥2
Baseline Characteristics
VIRTUS Clinical Trial | Efficacy Results
Definition:
Primary patency rate at 12 months post-intervention
- Freedom from occlusion by thrombosis
- Freedom from surgical or endovascular intervention on target vessel which are found to have re-stenosis or stent occlusion to maintain patency
- Freedom from in-stent stenosis more than 50% by venogram
Primary endpoint was met2
Primary patency rate exceeded the performance goal of 72.1% (p<0.0001)3,4
VIRTUS Clinical Trial | 12-Month Results
Safety Results:
98.8% freedom from MAEs through 30 days
Primary endpoint was met2:
Safety rate exceeded the performance goal of 94%5
Patient Outcomes:
- VIRTUS demonstrated a clinically meaningful 4.4 decrease in the VCSS score from baseline out to 12 months.
- Vici shifted patients with a severe VCSS score from almost 66% down to 27%,and increased the patients in the mild VCSS score 4-fold.
- 84% of patients experienced VCSS improvement.
VIRTUS Clinical Trial | Conclusions
VIRTUS primary safety and effectiveness endpoints successfully met:
Patient sample with challenging characteristics
Stay in-the-know
Subscribe now to receive venous stent updates.
Get to know more
From expert opinions to fact sheets, find what you need to help educate your patients.